Skip to main content
ZheJiang Tailin Bioengineering Co.,Ltd logo

ZheJiang Tailin Bioengineering Co.,Ltd — Investor Relations & Filings

Ticker · 300813 ISIN · CNE100003S89 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2025-03-11 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300813

About ZheJiang Tailin Bioengineering Co.,Ltd

https://www.tailingood.com

ZheJiang Tailin Bioengineering Co.,Ltd. specializes in the research, development, and manufacturing of high-tech equipment for life sciences and pharmaceutical engineering. The company provides integrated solutions for microbial control, sterility testing, and aseptic processing. Its core product portfolio includes sterility test canisters and pumps, microbial limit testing systems, and hydrogen peroxide vapor (VHP) decontamination units. Tailin also develops advanced isolator technology for containment and aseptic applications, alongside analytical instruments such as Total Organic Carbon (TOC) analyzers and filter integrity testers. These products are designed to meet international regulatory standards, including GMP, USP, and EP. The company serves sectors such as biopharmaceuticals, medical devices, and laboratory research, focusing on product safety and quality through specialized engineering and microbial detection technologies.

Recent filings

Filing Released Lang Actions
监事会关于公司2025年员工持股计划相关事项的审核意见
Board/Management Information Classification · 90% confidence The document is a supervisory board's review opinion on the company's 2025 employee stock ownership plan. It discusses compliance with regulatory guidelines, legality, and governance aspects of the employee stock plan. It does not contain financial statements or results, nor is it an announcement of voting results or a proxy solicitation. It is a formal management/board-level opinion related to governance and management decisions. Therefore, it fits best under Board/Management Information (MANG), which covers announcements related to company management decisions and governance matters.
2025-03-11 Chinese
关于收到浙江证监局警示函的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Zhejiang Tailin Biotechnology Co., Ltd. regarding receipt of a warning letter from the Zhejiang Securities Regulatory Bureau. It details regulatory compliance issues related to information disclosure violations and the company's response. The document does not contain financial statements, audit results, or detailed financial data. It is a regulatory announcement about legal and compliance matters, specifically a warning letter from a regulatory body. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories. The document length is short (1040 characters), and it is not a report or a certification but a regulatory announcement.
2025-02-25 Chinese
关于取得专利证书及计算机软件著作权登记证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Zhejiang Tailin Biotechnology Co., Ltd. regarding the acquisition of patent certificates and computer software copyright registration certificates. It details the specific patents and software copyrights obtained, their types, application numbers, and dates. The document emphasizes that these acquisitions do not have a significant impact on recent operations but enhance the company's intellectual property protection and innovation capabilities. The document is short (1140 characters) and is an announcement of intellectual property achievements rather than a financial report, management change, or other regulatory filing. It does not contain financial data, voting results, or legal proceedings. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2025-01-02 Chinese
第四届董事会第五次会议决议公告
Board/Management Information Classification · 100% confidence The document is an announcement of resolutions passed at a board meeting of Zhejiang Tailin Biotechnology Co., Ltd. It details the convening of the fourth board's fifth meeting, the agenda items discussed, and the voting results. The content focuses on board decisions such as approval of project investment delays, related party transactions, and the establishment of an internal policy. There is no financial data or comprehensive report content. The document is a formal disclosure of board meeting outcomes, which fits the category of Board/Management Information (MANG). The document length is short (1505 characters), and it is not a report or financial statement but an announcement of board decisions.
2024-12-31 Chinese
长城证券股份有限公司关于浙江泰林生物技术股份有限公司向不特定对象发行可转换公司债券募集资金投资项目延期的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from the sponsor institution (长城证券股份有限公司) regarding the postponement of an investment project funded by convertible bonds issued by 浙江泰林生物技术股份有限公司. It includes specifics about the fundraising, fund management, usage, project delays, board and supervisory approvals, and independent director opinions. The document references regulatory approvals and compliance with stock exchange rules. It is not a full financial report, earnings release, or audit report, but rather a regulatory compliance and project update related to capital raising and fund usage. The document length is under 5,000 characters, but it contains substantive content about the capital raising project and its delay, not merely an announcement of a report. Therefore, it fits best under Capital/Financing Update (CAP), as it provides an update on the company's fundraising and use of proceeds, including project delays and approvals.
2024-12-31 Chinese
舆情管理制度
Governance Information Classification · 95% confidence The document is a policy or internal regulation titled '舆情管理制度' (Public Opinion Management System) issued by Zhejiang Tailin Biotechnology Co., Ltd. It outlines the company's procedures and responsibilities for managing public opinion and media crises, including organizational structure, principles, and confidentiality obligations. There is no financial data, no mention of financial results, no regulatory filings, no shareholder meeting materials, no audit or legal proceedings, and no announcements related to capital or dividends. It is an internal governance document related to communication and crisis management policies. Therefore, it best fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules and governance practices.
2024-12-31 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.